Fort Lauderdale, FL., October 21st, 2010 - OmniComm Systems, Inc (OTC: OMCM.OB) today announced that it ranked number 220 on Technology Fast 500, Deloitte LLP's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on the percentage of fiscal year revenue growth during the period from 2005-2009. OmniComm grew 445 percent during this period.
OmniComm's CEO, Cornelis F. Wit, credits the expansion of its customer base in the US and Europe and the addition of its new product lines with the company's 445% revenue growth. "We are very pleased to be ranked on the Technology Fast 500 list for the third time in the last 5 years," said Mr. Wit. "Our growth has been steady with our existing EDC product line and the addition of our new eClinical product lines- including TrialOne for phase I automation and CDMS, CTMS, and Safety solutions- have allowed us to enter into new markets."
"OmniComm and the other 2010 Technology Fast 500 winners forged ahead in a challenging economic environment to realize exceptional growth" said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader. "Deloitte commends OmniComm for this impressive accomplishment."
"OmniComm has proved itself to be one of the fastest growing tech companies in North America, and we are proud to honor them as one of the 2010 Technology Fast 500," said Mark Jensen, managing partner, venture capital services, Deloitte & Touche LLP.
For additional detail on the Technology Fast 500 including selection and qualifying criteria, visit www.fast500.com
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company's commitment to deliver specific products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has a U.S. Headquarters in Fort Lauderdale, FL. and European headquarters in Bonn, Germany, with satellite offices in New Jersey, and the United Kingdom. There are sales offices throughout the U.S. and Europe.
As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.